Altimmune Axes Hepatitis B Program After Phase II Failure, Focuses on Obesity and MASH
28 Mar 2024
Phase 2Clinical Result
Pictured: 3d illustration of hepatitis B viruses/iStock/Artur Plawgo
Maryland-based Altimmune is eliminating its hepatitis B program after the company’s HepTcell candidate failed a Phase II trial, the biotech revealed Wednesday.
According to Altimmune, results from the Phase II trial investigating the efficacy of HepTcell showed it to be “insufficient to warrant further advancement” and that further development has been halted.
The candidate is an immunotherapeutic designed to drive CD4+ and CD8+ T-cell responses against all hepatitis B virus genotypes in patients. Phase I results, according to Altimmune, did manage to reach the primary endpoint of safety.
With Altimmune’s pullback from hepatitis B, the focus is now on the red-hot obesity market as the biotech’s candidate, pemvidutide, is showing encouraging data. In Phase II results for the injectable drug, released in November 2023, the company reported mean weight loss of 15% based on a 2.4-mg dose at week 48. At the highest pemvidutide dose level, more than 30% of patients lost at least 20% of their weight.
Pemvidutide is an investigational, peptide-based GLP-1/glucagon dual receptor agonistGLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). On Thursday, Altimmune touted the recently completed MOMENTUM 48-week Phase II obesity trial for pemvidutide.
“Our data show that 74.5% of weight loss was derived from adipose tissue and only 25.5% from lean mass, comparable to the effects historically associated with weight loss from diet and exercise programs,” Altimmune CEO Vipin Garg said in a statement.
The “compelling” weight loss data shows that pemvidutide can “distinguish itself” from other therapies in the obesity space, according to Garg, who added that the company is anticipating results from its Phase IIb MASH trial sometime in the first quarter of 2025.
Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.